Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Blessios

Surgery Williamsville, NY Medical Doctor

NPI 1669472080 CMS profile 29719

100 College Pkwy Ste 120, Williamsville, NY 14221

Open in the dashboard

General payments

$66,595

54 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Blessios of Williamsville, NY is reported in the CMS Open Payments database as having received $66,595 across 54 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,358 3
2024 General $28,192 9
2023 General $1,568 10
2022 General $589 3
2021 General $19 1
2020 General $26 2
2019 General $7,844 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Blessios
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to George Blessios were reported at $28,358. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year George Blessios Surgery median Middle half National median
2019 $7,844 $253 $82–$1,521 $163
2020 $26 $131 $40–$706 $114
2021 $19 $168 $50–$904 $132
2022 $589 $224 $76–$1,218 $149
2023 $1,568 $253 $82–$1,255 $160
2024 $28,192 $279 $90–$1,381 $164
2025 $28,358 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Laminate Medical Technologies inc. $56,549 12 payments
  2. W. L. Gore & Associates, Inc. $7,478 15 payments
  3. Medtronic, Inc. $1,826 13 payments
  4. Merit Medical Systems Inc $350 1 payment
  5. Philips Electronics North America Corporation $280 9 payments
  6. Celularity, Inc. $54 1 payment
  7. Cook Medical LLC $32 1 payment
  8. Boston Scientific Corporation $13 1 payment
  9. Avenu Medical Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $59,315 10 payments
  2. Travel and Lodging $3,042 11 payments
  3. Honoraria $2,625 2 payments
  4. Food and Beverage $1,612 31 payments
Products named General payments · program years 2019–2025
  1. VasQ $28,358 3 payments
  2. VasQ External Support $28,192 9 payments
  3. VIABAHN Endoprosthesis $5,593 5 payments
  4. VIABAHN Endoprosthesis with Heparin Bioactive Surface $1,877 9 payments
  5. ELLIPSYS VASCULAR ACCESS SYSTEM $1,807 12 payments
  6. Wrapsody Endovascular Stent Graft System $350 1 payment
  7. IGT D Peripheral $168 7 payments
  8. IGT D Service Syst $99 1 payment
  9. Biovance $54 1 payment
  10. Cook Medical Venous Access $32 1 payment
  11. Other $65 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

81

Median for Vascular Surgery: 122

Drug cost

$10,692

Median for Vascular Surgery: $14,135

Branded share of claims

74.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 17 $9,257
Enoxaparin Sodium Generic 21 $1,276
Acetaminophen-Codeine Acetaminophen With Codeine Brand 21 $111
Clopidogrel Clopidogrel Bisulfate Brand 22 $49

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$213,635

Of which drugs: $1,435

Medicare patients

131

Average age 67

Services billed

5,057

54 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 69%
Heart failure 61%
Ischemic heart disease 50%
Arthritis 45%
Atrial fibrillation 35%
COPD 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 42 3,500 $1,024

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

54 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record